Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

Human Gene Therapy
E GalanisS J Russell

Abstract

Malignant gliomas are the most common primary brain tumors in adults and, with few exceptions, have a dismal prognosis despite the therapeutic use of surgery, radiation therapy, and chemotherapy. Because CNS gliomas rarely metastasize, they represent an attractive target for gene therapy through local gene delivery. Here we report on the use of two different fusogenic membrane glycoproteins (FMGs), the measles virus proteins F and H (MV-F and MV-H) and a mutated form of the retroviral envelope protein of the gibbon ape leukemia virus (GALV.fus), as a novel class of therapeutic transgenes in gliomas. Transfection of U87 and U118 cells with MV-F and MV-H cDNA or GALV.fus cDNA led in 48 hr to massive syncytial formation followed by cell death. FMG-mediated cytotoxicity in the U87 and U118 cell lines was superior to the cytotoxicity caused by transfection with HSV-tk cDNA followed by ganciclovir (GCV) treatment at all time points. At high-density cell seeding, addition of tumor cells transfected with MV-F and H killed at least 1 log more cells than by HSV-tk + GCV treatment, indicating higher bystander effect. Similar results were obtained with GALV.fus. The mechanism of syncytial death in cultured glioma cell lines was predominant...Continue Reading

References

Jun 1, 1995·Journal of Virology·L M EsolenD E Griffin
Nov 1, 1996·Journal of Virology·N MitterederB C Trapnell
Nov 5, 1997·Nature Biotechnology·R ZuffereyD Trono
Mar 14, 1998·Journal of Virology·P SpielhoferH Y Naim

❮ Previous
Next ❯

Citations

Oct 28, 2003·Human Gene Therapy·Keith Bupp, Monica J Roth
May 25, 2010·Neuro-oncology·Adam W StudebakerCorey Raffel
Feb 1, 2012·The Cancer Journal·Guido WollmannAnthony N van den Pol
Dec 21, 2004·Immunology·Marka R CrittendenMichael J Gough
Sep 7, 2007·Journal of Virology·Kosei HasegawaKah-Whye Peng
Nov 2, 2012·Molekuliarnaia biologiia·V A SviatchenkoP M Chumakov
Aug 10, 2006·Biological Chemistry·Sascha DrewloAndy J G Pötgens
Nov 3, 2011·Bone Marrow Research·Chandini M Thirukkumaran, Don G Morris
Feb 6, 2010·Expert Opinion on Biological Therapy·Karoly TothWilliam S M Wold
Jan 16, 2008·Expert Opinion on Biological Therapy·Cory AllenEvanthia Galanis
Jan 8, 2013·Expert Opinion on Biological Therapy·Pavlos MsaouelEvanthia Galanis
Jun 11, 2003·The Journal of Gene Medicine·A Gómez-TreviñoE Mercadé
Aug 10, 2010·Virus Research·Jose I QuetglasCristian Smerdou
Oct 26, 2007·The Journal of Investigative Dermatology·Dennis HoffmannOliver Wildner
Sep 16, 2004·The Journal of Gene Medicine·Jie ZhangStephen J Russell
Mar 14, 2007·The Journal of Gene Medicine·Sophy ZhengMaciej S Lesniak
Nov 30, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Boris BlechaczNicholas F LaRusso
Feb 14, 2002·The Journal of General Virology·Christopher J A Ring
Apr 30, 2002·Placenta·A J G PötgensH-G Frank
Dec 8, 2015·Molecular Therapy Oncolytics·Olga V MatveevaPeter M Chumakov
Oct 27, 2016·Viruses·Sarah ArefAdele Fielding
Nov 23, 2016·Cancer·Anastasie M Dunn-Pirio, Gordana Vlahovic
Mar 3, 2004·Nature Biotechnology·Takafumi NakamuraStephen J Russell
Apr 15, 2003·Human Gene Therapy·Anthony M BradeHenry J Klamut
Oct 9, 2004·Cancer Gene Therapy·Bart Everts, Henk G van der Poel
Jul 13, 2002·Expert Review of Anticancer Therapy·Yehoshua GdorTimothy C Thompson
Feb 2, 2018·Skeletal Muscle·Srihari C SampathDouglas P Millay
Oct 1, 2010·Clinical Pharmacology and Therapeutics·E Galanis
Dec 20, 2017·Oncotarget·Christos FountzilasDevalingam Mahalingam

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.